TrialBreast cancer research and treatment2026

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Norikazu Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.